Premier Alternatives

Interius BioTherapeutics

Philadelphia, PA · Founded 2019 · Privately Held (backing)

Developer of a genetic medicines precision delivery platform intended to treat hematologic malignancies. Interius BioTherapeutics is based in Philadelphia, PA and was founded in 2019. It was valued at $350 million at a merger or acquisition in Oct 2025, the last priced event on record. It has raised $170 million across 4 recorded rounds; the latest was a $51.4 million later-stage round in May 2024.

PMV mark · valuation
$350.0M
Oct 2026
Priced at
a merger or acquisition
Oct 2025
Total raised
$169.6M
Last round
Later Stage VC
May 2024

Interius BioTherapeutics key facts

as of Oct 2026
  • Developer of a genetic medicines precision delivery platform intended to treat hematologic malignancies.
  • Interius BioTherapeutics is valued at approximately $350.0M as of Oct 2026, set at a merger or acquisition, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $169.6M across 4 recorded rounds; the latest was Later Stage VC ($51.4M) in May 2024.
  • Notable investors include Osage University Partners, Cormorant Asset Management, Pfizer Ventures, Logos Capital, Knollwood Investment Advisory — 20 tracked in total.
  • Interius BioTherapeutics has filed 4 Form Ds with the SEC since 2020, most recently Jun 2024 ($51.4M sold to 12 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$350.0M

Valued at $350.0M at a merger or acquisition, Oct 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Interius BioTherapeutics with a free account
  • ·The complete investor list: 20 names
  • ·Watch Interius BioTherapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Interius BioTherapeutics funding rounds

4 rounds
May 2024Later Stage VC$51.4MSEC filing▮
Oct 2023Debt$21.5MSEC filing▮
May 2021Early Stage VC$43.6MSEC filing▮
Mar 2020Seed Round$1.6MSEC filing▮
Full funding history →

Interius BioTherapeutics valuation

Interius BioTherapeutics was valued at $350 million at a merger or acquisition in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Interius BioTherapeutics raised?

Interius BioTherapeutics has raised $170 million across 4 recorded rounds since 2020. The largest was a $51.4 million later-stage round in May 2024.

Interius BioTherapeutics has filed 4 Form Ds with the SEC since 2020, most recently in Jun 2024 ($51.4 million sold to 12 investors).

Interius BioTherapeutics investors

20 investors are on record for Interius BioTherapeutics, including Osage University Partners, Cormorant Asset Management, Pfizer Ventures and Logos Capital. By type, the record holds 4 venture capital firms and 1 hedge fund. The later-stage round in May 2024 drew 12 investors.

About Interius BioTherapeutics

Developer of a genetic medicines precision delivery platform intended to treat hematologic malignancies. The company's platform develops chimeric antigen receptor T cells directly in vivo, bypassing the need for ex vivo cell manipulations and the potentially toxic preconditioning chemotherapy required for standard CAR T-cell treatments, enabling clinicians to provide therapies to treat an array of challenging diseases for patients.

Sector
Healthcare
HQ
Philadelphia, PA, United States
Founded
2019
Employees
52
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.